ANDA 206387, held by Ipca Labs Ltd. Alendronate Sodium.
As of Nov 16, 2026, ANDA 206387 (Alendronate Sodium), held by Ipca Labs Ltd, was first approved by FDA on Jun 4, 2024, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 4, 2024 | Original application | Approved | None posted |
| Alendronate SodiumEQ 10MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 35MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 40MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 70MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Apr 15, 2026 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 4, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters